Lifeward Ltd. has successfully conducted its 2026 Annual and Extraordinary General Meeting of Shareholders, where significant proposals were voted upon. This meeting, held on October 30, 2026, saw shareholders approving several key matters that will shape the company's governance and operational strategies moving forward.

During the meeting, an aggregate of 2,036,125 ordinary shares, representing approximately 71.7% of the total shares issued and outstanding, were present or voted, constituting a quorum. The proposals covered a range of topics, including the re-election of directors, compensation policies, and the appointment of external directors.

Company Background

Lifeward Ltd., incorporated in Israel, operates in the orthopedic, prosthetic, and surgical appliances and supplies industry, as classified under SIC code 3842. The company is publicly traded on the Nasdaq under the ticker symbol LFWD. Lifeward has undergone several name changes in its history, previously known as ReWalk Robotics Ltd. and Argo Medical Technologies Ltd.

What the Filing Says

The SEC filing reveals that the following proposals were voted on:

  • Proposal No. 1.a: Re-election of Haggai Zamir as a Class III director received 1,353,461 votes in favor, with 92,843 against.
  • Proposal No. 1.b: Re-election of Avi Gabay as a Class III director also passed with 1,353,446 votes for and 92,945 against.
  • Proposal No. 2: Election of Ariel Kallner as an external director was approved with 101,440 votes for and 94,548 against.
  • Proposal No. 3: Approval of equity compensation for directors was supported by 99,369 votes for and 96,000 against.
  • Proposal No. 4: Compensation for Interim CEO Josh Hexter was approved with 133,187 votes for and 98,732 against.
  • Proposal No. 5: Approval for the issuance of ordinary shares upon conversion of notes was passed with 1,351,136 votes for.
  • Proposal No. 6: Renewal of the compensation policy for officers and directors was not approved, receiving only 95,657 votes for against 99,427.
  • Proposal No. 7: Re-appointment of Kost Forer Gabbay & Kasierer as the independent auditor was overwhelmingly approved.
  • Proposal No. 8: Advisory vote on executive compensation was also approved.

Impact

The results of this meeting will have significant implications for Lifeward Ltd.'s governance structure and operational policies. The approval of key directors and compensation for the interim CEO indicates shareholder support for the current leadership. However, the rejection of the compensation policy renewal raises questions about the future compensation strategies for officers and directors, which could affect recruitment and retention of top talent in the competitive orthopedic and prosthetic industry.

What's Next

The filing does not say what happens next regarding the compensation policy or any adjustments the company may make in light of the shareholder vote.